N. Nora Bennani

Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

Loretta J. Nastoupil, Michael D. Jain, Lei Feng et al. · Journal of Clinical Oncology · 2020 · 786 citations · Full text

Medicine, Hematology, Oncology +17

Clinicopathological features, treatment approaches, and outcomes in Rosai-Dorfman disease

Gaurav Goyal, Aishwarya Ravindran, Jason R. Young et al. · Haematologica · 2019 · 218 citations · Full text

Medicine, Oncology, Pathology +12

The Mayo Clinic Histiocytosis Working Group Consensus Statement for the Diagnosis and Evaluation of Adult Patients With Histiocytic Neoplasms: Erdheim-Chester Disease, Langerhans Cell Histiocytosis, and Rosai-Dorfman Disease

Gaurav Goyal, Jason R. Young, Matthew J. Koster et al. · Mayo Clinic Proceedings · 2019 · 191 citations

Veterinary Medicine, Pathology, Cellular Pathology +12

Molecular profiling reveals immunogenic cues in anaplastic large cell lymphomas with DUSP22 rearrangements

Rebecca A. Luchtel, Surendra Dasari, Naoki Oishi et al. · Blood · 2018 · 116 citations · Full text

Medicine, Molecular Biology, Oncology +15

Axicabtagene Ciloleucel (Axi-cel) CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy for Relapsed/Refractory Large B-Cell Lymphoma: Real World Experience

Loretta J. Nastoupil, Michael D. Jain, Jay Y. Spiegel et al. · Blood · 2018 · 113 citations

Medicine, Hematology, Oncology +17